363140-31-2

Basic information

• Product Name: Carbamic acid, (2-methoxy-5-methylphenyl)-, (3-endo)-9-(phenylmethyl)-9-azabicyclo[3.3.1]non-3-yl ester
• CAS NO: 363140-31-2
• Molecular Formula: C24H30N2O3
• Molecular Weight: 394.514
• Mol File: 363140-31-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (2-methoxy-5-methylphenyl)-, (3-endo)-9-(phenylmethyl)-9-azabicyclo[3.3.1]non-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (2-methoxy-5-methylphenyl)-, (3-endo)-9-(phenylmethyl)-9-azabicyclo[3.3.1]non-3-yl ester(363140-31-2)
• EPA Substance Registry System: Carbamic acid, (2-methoxy-5-methylphenyl)-, (3-endo)-9-(phenylmethyl)-9-azabicyclo[3.3.1]non-3-yl ester(363140-31-2)

Safety Data

• Hazardous Substances Data: 363140-31-2(Hazardous Substances Data)

Upstream product

• 70243-51-5 3-endo-hydroxy-9-benzyl-9-azabicyclo[3.3.1]nonane 
• 59741-04-7 2-methoxy-5-methylphenyl isocyanate 

Downstream Products

• 913815-84-6 N-(9-(6-aminodecyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate 
• 1036759-20-2 (2-Methoxy-5-methyl-phenyl)-carbamic acid (1R,3R,5S)-9-[10-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-decyl]-9-aza-bicyclo[3.3.1]non-3-yl ester 
• 1036759-16-6 (2-Methoxy-5-methyl-phenyl)-carbamic acid (1R,3R,5S)-9-[6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-hexyl]-9-aza-bicyclo[3.3.1]non-3-yl ester 
• 913815-82-4 N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate 
• 371226-24-3 9-[(4-tert-butoxyformamido)phenethyl]-9-azabicyclo[3.3.1]nonan-3α-yl N-(2-methoxy-5-methylphenyl)carbamate 

Relevant articles and documents

SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC50 value below 5 μΜ against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

Azabicyclo[3.2.1]octan-3α-yl and azabicyclo[3.3.1]nonan-3α-yl carbamates as σ2-selective radiotracers

-